

Cover Story
Relying largely on maturing data from the European trials of screening for prostate cancer, the U.S. Preventive Services Task Force has given a better grade—a “C”—to screening for prostate cancer.
By Matthew Bin Han Ong
In Brief
Funding Opportunities
Clinical Roundup
Drugs & Targets
Trending Stories
- Tidmarsh is out, Pazdur is in: FDA’s CDER under new leadership
- Christine Lovly to lead City of Hope’s new national thoracic oncology program
- FDA to remove black box warnings on hormone therapy for menopause
Trump-era “gold standard science” is not to be confused with gold standard of scientific evidence - Rick Pazdur’s CDER appointment comes at exactly the right moment for FDA
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- Smoldering multiple myeloma: Rethinking the waiting game




















